ALSO IN THIS MONTH'S ISSUE
The Future Of The Life Sciences Industry And What You Need To Know
The industry must now prepare to respond to multiple converging trends — some new and some old — but all profoundly affected by the COVID-19 pandemic and in the coming post-pandemic environment.
Companies To Watch: Castle Creek Biosciences
For Castle Creek Biosciences, there are many stakes at play in targeting rare skin, connective tissue, liver, and metabolic disorders.
Platforms To Pipelines: Part 2
In part 2 of this series, we cover each company’s future plans, as well as their leaders’ observations of the platform-to-pipeline space they are effectively expanding, by joining a gathering crowd of companies now entering it.
Is A Key Function To Product Launch Excellence Being Overlooked?
Learn how medical affairs can help propel product launches for highly complex therapies.
BEYOND THE PRINTED PAGE
MAPS: Walking The Talk On Intellectual Property?4/29/2022
Did MAPS, a leader in the psychedelic medicines space, just make good on its promise to share its intellectual property, as opposed to wielding it against competitors?
Where Patients Meet Policy: The EveryLife Foundation For Rare Diseases4/1/2022
The year before he founded Ultragenyx, Emil Kakkis created the EveryLife Foundation for Rare Diseases, a nonprofit patient advocacy organization focused on the “equitable development of and access to lifesaving diagnoses, treatments, and cures.” We caught up with Annie Kennedy, chief of policy and advocacy at the EveryLife Foundation, to learn more about the issues and policies the foundation is prioritizing this year.
Ever Learn A Lesson The Hard Way?1/24/2022
Bernard Coulie, M.D., Ph.D., president and CEO of Pliant Therapeutics, a company developing treatments for fibrotic diseases, shares a lesson learned the hard way involving an exit from a previous startup.